中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(1): 135-140

Efficacy of artificial liver support system in treatment of acute-on-chronic liver failure: A network Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2022.01.021

  • Department of Critical Care Medicine, Gansu Provincial Hospital, Lanzhou 730000, China

Research funding:

Hospital Fund of Gansu Provincial Hospital (18GSSY6-5)

  • Received Date: 2021-07-30
  • Accepted Date: 2021-08-31
  • Published Date: 2022-01-20
    Abstract
  •   Objective  To systematically review the efficacy of different artificial liver support systems in the treatment of acute-on-chronic liver failure (ACLF) using a network Meta-analysis.  Methods  PubMed, Embase, the Cochrane library, Clinical Trial, CNKI, SinoMed, and Wanfang Data were searched for randomized controlled trials (RCTs) on different artificial liver support systems in the treatment of ACLF. Literature screening, data extraction, and method ological quality assessment were performed according to inclusion and exclusion criteria, and Stata15.1 software and R4.1.0 software were used to perform a network Meta-analysis.  Results  A total of 14 RCTs were included, with 1141 patients in total. The network meta-analysis showed different intervention methods had no significant difference in reducing mortality rate based on cross comparison (all P > 0.05). The probability ranking diagram showed that plasma exchange (PE) showed the best effect in reducing 30-day mortality rate, followed by extracorporeal liver assist device (ELAD), fractionated plasma separation and adsorption with Prometheus system, molecular adsorbent recirculating system (MARS), Biologic-DT liver dialysis device, and PE+MARS. PE showed the best effect in reducing 90-day mortality rate, followed by Prometheus, ELAD, and MARS. Biologic-DT showed the best effect in improving hepatic encephalopathy, followed by MARS, PE+MARS, and ELAD. Patients undergoing ELAD had the lowest risk of bleeding, and compared with standard medical treatment, Biologic-DT might increase the risk of bleeding [risk ratio=1.9×108, 95% confidence interval: (4.6-6.2)×1027].  Conclusion  PE might be the best option for reducing 30- and 90-day mortality rates in ACLF patients. Biologic-DT has a better effect in improving hepatic encephalopathy, but it may increase the risk of bleeding.

     

    • FullText(HTML)
  • loading
    • References(31)
  • [1]
    SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
    [2]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [3]
    ARROYO V, MOREAU R, JALAN R. Acute-on-chronic liver failure[J]. N Engl J Med, 2020, 382(22): 2137-2145. DOI: 10.1056/NEJMra1914900.
    [4]
    ARTRU F, LOUVET A, RUIZ I, et al. Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3[J]. J Hepatol, 2017, 67(4): 708-715. DOI: 10.1016/j.jhep.2017.06.009.
    [5]
    OLIVO R, GUARRERA JV, PYRSOPOULOS NT. Liver transplantation for acute liver failure[J]. Clin Liver Dis, 2018, 22(2): 409-417. DOI: 10.1016/j.cld.2018.01.014.
    [6]
    ALSHAMSI F, ALSHAMMARI K, BELLEY-COTE E, et al. Extracorporeal liver support in patients with liver failure: A systematic review and meta-analysis of randomized trials[J]. Intensive Care Med, 2020, 46(1): 1-16. DOI: 10.1007/s00134-019-05783-y.
    [7]
    KHUROO MS, KHUROO MS, FARAHAT KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: A meta-analysis[J]. Liver Transpl, 2004, 10(9): 1099-1106. DOI: 10.1002/lt.20139.
    [8]
    STUTCHFIELD BM, SIMPSON K, WIGMORE SJ. Systematic review and meta-analysis of survival following extracorporeal liver support[J]. Br J Surg, 2011, 98(5): 623-631. DOI: 10.1002/bjs.7418.
    [9]
    KJAERGARD LL, LIU J, ALS-NIELSEN B, et al. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: A systematic review[J]. JAMA, 2003, 289(2): 217-222. DOI: 10.1001/jama.289.2.217.
    [10]
    VAID A, CHWEICH H, BALK EM, et al. Molecular adsorbent recirculating system as artificial support therapy for liver failure: A meta-analysis[J]. ASAIO J, 2012, 58(1): 51-59. DOI: 10.1097/MAT.0b013e31823fd077.
    [11]
    STERNE J, SAVOVI C ' J, PAGE MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials[J]. BMJ, 2019, 366: l4898. DOI: 10.1136/bmj.l4898.
    [12]
    ZHOU R, GAN QR, ZHENG CX, et al. Analysis on the effects of artificial liver support system on prognosis of patients with later period of chronic severe hepatitis B and selection of proper analytical method[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2012, 6(3): 186-190. DOI: 10.3877/cma.j.issn.1674-1358.2012.03.003.

    周锐, 甘巧蓉, 郑彩霞, 等. 人工肝对晚期慢性乙型重型肝炎预后影响及分析方法的选择[J/CD]. 中华实验和临床感染病杂志(电子版), 2012, 6(3): 186-190. DOI: 10.3877/cma.j.issn.1674-1358.2012.03.003.
    [13]
    BAÑARES R, NEVENS F, LARSEN FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial[J]. Hepatology, 2013, 57(3): 1153-1162. DOI: 10.1002/hep.26185.
    [14]
    DUAN Z, XIN S, ZHANG J, et al. Comparison of extracorporeal cellular therapy (ELAD(®)) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure[J]. Hepat Med, 2018, 10: 139-152. DOI: 10.2147/HMER.S180246.
    [15]
    HASSANEIN TI, TOFTENG F, BROWN RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis[J]. Hepatology, 2007, 46(6): 1853-1862. DOI: 10.1002/hep.21930.
    [16]
    HEEMANN U, TREICHEL U, LOOCK J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study[J]. Hepatology, 2002, 36(4 Pt 1): 949-958. DOI: 10.1053/jhep.2002.36130.
    [17]
    HILLEBRAND DJ, FREDERICK RT, WILLIAMS WW, et al. Safety and efficacy of the Extracorporeal Liver Assist Device (ELAD®) in patients with acute on chronic liver failure[J]. J Hepatol, 2010, 52: s323-s324. DOI: 10.1016/S0168-8278(10)60830-6.
    [18]
    HUANG YK, TAN DM, XIE YT, et al. Randomized controlled study of plasma exchange combined with molecular adsorbent re-circulating system for the treatment of liver failure complicated with hepatic encephalopathy[J]. Hepatogastroenterology, 2012, 59(117): 1323-1326. DOI: 10.5754/hge12203.
    [19]
    KRAMER L, GENDO A, MADL C, et al. A controlled study of sorbent suspension dialysis in chronic liver disease and hepatic encephalopathy[J]. Int J Artif Organs, 2001, 24(7): 434-442. http://www.onacademic.com/detail/journal_1000041651484399_80ae.html
    [20]
    KRIBBEN A, GERKEN G, HAAG S, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure[J]. Gastroenterology, 2012, 142(4): 782-789. e3. DOI: 10.1053/j.gastro.2011.12.056.
    [21]
    LALEMAN W, WILMER A, EVENEPOEL P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure[J]. Crit Care, 2006, 10(4): R108. DOI: 10.1186/cc4985.
    [22]
    MITZNER SR, STANGE J, KLAMMT S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial[J]. Liver Transpl, 2000, 6(3): 277-286. DOI: 10.1002/lt.500060326.
    [23]
    QIN G, SHAO JG, WANG B, et al. Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: A single-center experience[J]. Medicine (Baltimore), 2014, 93(28): e338. DOI: 10.1097/MD.0000000000000338.
    [24]
    SEN S, DAVIES NA, MOOKERJEE RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study[J]. Liver Transpl, 2004, 10(9): 1109-1119. DOI: 10.1002/lt.20236.
    [25]
    THOMPSON J, JONES N, AL-KHAFAJI A, et al. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial[J]. Liver Transpl, 2018, 24(3): 380-393. DOI: 10.1002/lt.24986.
    [26]
    TOFT N, INNOCENT GT, GETTINBY G, et al. Assessing the convergence of Markov Chain Monte Carlo methods: An example from evaluation of diagnostic tests in absence of a gold standard[J]. Prev Vet Med, 2007, 79(2-4): 244-256. DOI: 10.1016/j.prevetmed.2007.01.003.
    [27]
    MEZZANO G, JUANOLA A, CARDENAS A, et al. Global burden of disease: Acute-on-chronic liver failure, a systematic review and meta-analysis[J]. Gut, 2021. DOI: 10.1136/gutjnl-2020-322161.[Epub ahead of print].
    [28]
    MEDZHITOV R. Inflammation 2010: New adventures of an old flame[J]. Cell, 2010, 140(6): 771-776. DOI: 10.1016/j.cell.2010.03.006.
    [29]
    SARIN SK, CHOUDHURY A. Acute-on-chronic liver failure: Terminology, mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(3): 131-149. DOI: 10.1038/nrgastro.2015.219.
    [30]
    GARCÍA MARTÍNEZ JJ, BENDJELID K. Artificial liver support systems: What is new over the last decade?[J]. Ann Intensive Care, 2018, 8(1): 109. DOI: 10.1186/s13613-018-0453-z.
    [31]
    TAN EX, WANG MX, PANG J, et al. Plasma exchange in patients with acute and acute-on-chronic liver failure: A systematic review[J]. World J Gastroenterol, 2020, 26(2): 219-245. DOI: 10.3748/wjg.v26.i2.219.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(6)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1245) PDF downloads(102) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return